Bristol-Myers Squibb Pulls Vanlev
PRINCETON, NJ- Vanlev, the first antihypertensive drug to receive priority review by the Food and Drug Administration (FDA), has been withdrawn from the approval process. Bristol-Myers Squibb voluntarily pulled the application due to questions raised by the FDA regarding a potential side effect. Though infrequent, the possibility of angioedema, a localized swelling affecting the face, throat, lips, or tongue, has been cited in some cases. Vanlev was designed to inhibit simultaneously two key enzymes, the angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) that regulate blood pressure. Studies have shown that the drug significantly reduces both systolic and diastolic blood pressure. The company hopes to resubmit the application early next year after new data has been compiled.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.